VASOCIDIN

Clinical safety rating: caution

Comprehensive clinical and safety monograph for VASOCIDIN (VASOCIDIN).

How it works

Vasocidin is a combination of sulfacetamide sodium, a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, thereby blocking folate synthesis and bacterial growth, and prednisolone sodium phosphate, a corticosteroid that suppresses inflammation by inhibiting phospholipase A2 and subsequent prostaglandin and leukotriene synthesis.

What the body does with it

Metabolism	Sulfacetamide is primarily metabolized via acetylation in the liver; prednisolone is metabolized via hepatic metabolism by cytochrome P450 enzymes (primarily CYP3A4) and reduction reactions.
Excretion	Renal: 70-80% as unchanged drug; biliary/fecal: 20-30% as metabolites and unchanged drug.
Half-life	Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged in renal impairment.
Protein binding	20-30% bound to plasma proteins (primarily albumin).
Volume of Distribution	0.2-0.3 L/kg; indicates distribution primarily into extracellular fluid.
Bioavailability	Ophthalmic: negligible systemic absorption (<5%) after topical administration.
Onset of Action	Ophthalmic: 15-30 minutes after topical administration.
Duration of Action	Ophthalmic: 4-6 hours; clinical effect may persist longer with repeated dosing.

Classification & Brands

Dosing & administration

One drop of the ophthalmic suspension into the conjunctival sac of the affected eye(s) every 4 hours while awake and at bedtime for 7 days; duration may be extended based on clinical response.

Dosage form	OINTMENT
Renal impairment	No specific guidelines for ophthalmic use; systemic absorption is minimal. For suspected systemic toxicity, adjust based on prednisolone and sulfacetamide components.
Liver impairment	No specific guidelines for ophthalmic use; systemic absorption is minimal. Use with caution in severe hepatic impairment due to potential corticosteroid effects.
Pediatric use	Children ≥2 years: one drop into affected eye(s) every 4 hours while awake and at bedtime for 7 days. Safety and efficacy in children <2 years not established.
Geriatric use	No specific dose adjustment required; use same dosing as adults. Monitor for increased intraocular pressure or delayed healing due to corticosteroid component.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for VASOCIDIN (VASOCIDIN).

Breastfeeding	It is not known whether topical ophthalmic sulfacetamide or prednisolone are excreted in human milk. Systemic corticosteroids appear in breast milk and could suppress growth or interfere with endogenous corticosteroid production. Caution should be exercised when administered to a nursing woman. M/P ratio unknown.
Teratogenic Risk	Pregnancy Category C. No adequate studies in pregnant women. In animal studies, corticosteroids have been shown to be teratogenic at high doses. Sulfacetamide may cause kernicterus if used near term due to displacement of bilirubin from albumin. Avoid use in pregnant women unless potential benefit outweighs risk.

Warnings & precautions

■ FDA Black Box Warning

Sulfonamides are associated with severe hypersensitivity reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and fatalities; use caution in patients with known sulfonamide allergy.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to sulfonamides or prednisolone","Ocular herpes simplex","Fungal or viral infections of the eye (e.g., vaccinia, varicella, epithelial herpes simplex keratitis)","Mycobacterial infections of the eye"]

Clinical Precautions

Precautions

["Prolonged use may lead to cataract formation, elevated intraocular pressure, glaucoma, and secondary ocular infections","Hypersensitivity reactions including anaphylaxis and skin reactions possible","May mask signs of bacterial, fungal, or viral infections","Not for injection; ophthalmic use only"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

VASOCIDIN

Clinical safety rating: caution

Comprehensive clinical and safety monograph for VASOCIDIN (VASOCIDIN).

How it works

What the body does with it

Metabolism	Sulfacetamide is primarily metabolized via acetylation in the liver; prednisolone is metabolized via hepatic metabolism by cytochrome P450 enzymes (primarily CYP3A4) and reduction reactions.
Excretion	Renal: 70-80% as unchanged drug; biliary/fecal: 20-30% as metabolites and unchanged drug.
Half-life	Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged in renal impairment.
Protein binding	20-30% bound to plasma proteins (primarily albumin).
Volume of Distribution	0.2-0.3 L/kg; indicates distribution primarily into extracellular fluid.
Bioavailability	Ophthalmic: negligible systemic absorption (<5%) after topical administration.
Onset of Action	Ophthalmic: 15-30 minutes after topical administration.
Duration of Action	Ophthalmic: 4-6 hours; clinical effect may persist longer with repeated dosing.

Classification & Brands

Dosing & administration

One drop of the ophthalmic suspension into the conjunctival sac of the affected eye(s) every 4 hours while awake and at bedtime for 7 days; duration may be extended based on clinical response.

Dosage form	OINTMENT
Renal impairment	No specific guidelines for ophthalmic use; systemic absorption is minimal. For suspected systemic toxicity, adjust based on prednisolone and sulfacetamide components.
Liver impairment	No specific guidelines for ophthalmic use; systemic absorption is minimal. Use with caution in severe hepatic impairment due to potential corticosteroid effects.
Pediatric use	Children ≥2 years: one drop into affected eye(s) every 4 hours while awake and at bedtime for 7 days. Safety and efficacy in children <2 years not established.
Geriatric use	No specific dose adjustment required; use same dosing as adults. Monitor for increased intraocular pressure or delayed healing due to corticosteroid component.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for VASOCIDIN (VASOCIDIN).

Breastfeeding	It is not known whether topical ophthalmic sulfacetamide or prednisolone are excreted in human milk. Systemic corticosteroids appear in breast milk and could suppress growth or interfere with endogenous corticosteroid production. Caution should be exercised when administered to a nursing woman. M/P ratio unknown.
Teratogenic Risk	Pregnancy Category C. No adequate studies in pregnant women. In animal studies, corticosteroids have been shown to be teratogenic at high doses. Sulfacetamide may cause kernicterus if used near term due to displacement of bilirubin from albumin. Avoid use in pregnant women unless potential benefit outweighs risk.